kukoamine B mesilate / Tianjin Chase Sun Pharma - LARVOL DELTA

Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients (clinicaltrials.gov) - P2 | N=424 | Recruiting | Sponsor: Tianjin Chasesun Pharmaceutical Co., LTD | Trial completion date: Mar 2024 ➔ Jun 2024 | Trial primary completion date: Feb 2024 ➔ May 2024

Trial completion date • Trial primary completion date • Infectious Disease • Septic Shock

Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients (clinicaltrials.gov) - P2 | N=424 | Recruiting | Sponsor: Tianjin Chasesun Pharmaceutical Co., LTD | Trial primary completion date: Aug 2023 ➔ Feb 2024

Trial primary completion date • Infectious Disease • Septic Shock

Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients (clinicaltrials.gov) - P2 | N=424 | Recruiting | Sponsor: Tianjin Chasesun Pharmaceutical Co., LTD | Trial primary completion date: May 2024 ➔ Aug 2023

Trial primary completion date • Infectious Disease • Septic Shock • IL6

Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients (clinicaltrials.gov) - P2; N=424; Recruiting; Sponsor: Tianjin Chasesun Pharmaceutical Co., LTD; Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Septic Shock • IL6

Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients (clinicaltrials.gov) - P2; N=424; Not yet recruiting; Sponsor: Tianjin Chasesun Pharmaceutical Co., LTD

Clinical • New P2 trial • Infectious Disease • Septic Shock • IL6

Study of Multiple-dose Kukoamine B Mesilate in Sepsis Patients (clinicaltrials.gov) - P1; N=44; Completed; Sponsor: Tianjin Chasesun Pharmaceutical Co., LTD; Recruiting ➔ Completed; Trial completion date: Dec 2019 ➔ Sep 2019; Trial primary completion date: Dec 2019 ➔ Sep 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date